438 related articles for article (PubMed ID: 31729053)
1. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
[TBL] [Abstract][Full Text] [Related]
2. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate Elimination When Coadministered With Levetiracetam.
Reeves D; DiDominick S; Finn S; Kim HJ; Shake A
Ann Pharmacother; 2016 Dec; 50(12):1016-1022. PubMed ID: 27511814
[TBL] [Abstract][Full Text] [Related]
5. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Bain E; Birhiray RE; Reeves DJ
Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Wippel B; Gundle KR; Dang T; Paxton J; Bubalo J; Stork L; Fu R; Ryan CW; Davis LE
Cancer Med; 2019 Jan; 8(1):111-116. PubMed ID: 30580500
[TBL] [Abstract][Full Text] [Related]
8. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
9. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
10. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate for primary CNS lymphoma in the elderly.
Ng S; Rosenthal MA; Ashley D; Cher L
Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
[TBL] [Abstract][Full Text] [Related]
13. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
[TBL] [Abstract][Full Text] [Related]
14. Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage.
Mangum R; Bernhardt MB; Cheng WS; Schafer ES; Berg SL; Foster JH
Pediatr Blood Cancer; 2020 Sep; 67(9):e28334. PubMed ID: 32608575
[TBL] [Abstract][Full Text] [Related]
15. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia.
Orgel E; Nabais T; Douglas C; Mittelman SD; Neely M
J Clin Pharmacol; 2021 Jun; 61(6):755-762. PubMed ID: 33314168
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
18. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Ranchon F; Vantard N; Henin E; Bachy E; Sarkozy C; Karlin L; Bouafia-Sauvy F; Gouraud A; Schwiertz V; Bourbon E; Baudouin A; Caffin AG; Vial T; Salles G; Rioufol C
Hematol Oncol; 2018 Apr; 36(2):399-406. PubMed ID: 28983943
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]